Our Research & Development
A word from…
To enable Servier to achieve its transformation objectives by 2025, R&D has developed an initial three-year action plan. The idea is to discover and develop new medicines where patient needs are greatest.
Servier organizes its R&D in 4 therapeutic areas where it has extensive know-how and renowned expertise and in which there are high unmet patient needs: oncology, neuroscience, immuno-inflammatory diseases, as well as cardiovascular and metabolic diseases.
R&D key figures
of revenue from brand-name medicines invested in R&D each year
of the Servier global R&D budget* dedicated to researching cancer treatments
* brand-name activity
active alliances worldwide
Symphogen Focus, subsidiary of the Servier Group
Founded in 2000 and based in Denmark, Symphogen is a biotech company that has developed an efficient discovery and research platform that can rapidly identify high quality monoclonal and bi-specific antibodies supported by early development capabilities with strong in vitro and in vivo capacities across oncology and immuno-oncology. Symphogen is organized as a combined project and line organization with various research, pre-clinical, CMC (Chemistry, Manufacturing and Control), clinical and regulatory departments.
As part of the acquisition by Servier, Symphogen becomes the antibody center of excellence of the Group as its platform can deliver antibodies with unique functionalities providing best or first in class potential.
READ MORE →Therapeutic areas
See moreServier Paris-Saclay R&D Institute
See moreClinical trials
See moreOur development portfolio
See moreRegulatory affairs
See morePharmacovigilance
See moreLast news
